Late Motherhood To Drive The Prenatal Testing Market

Date : Mar 31, 2021 Author : PMR Editorial Staff Category : Healthcare

Need for Prenatal testing

There is no denial to the fact that the childbearing age these days has undergone a paradigm shift due to several economic and social factors. This has, in turn, turned the tide towards Down syndrome babies (as late child disturbs the biological clock, thereby resulting in complexities in the fetal growth).

The modern-day concerns regarding fetal growth are chromosomal abnormalities, malformed kidneys, congenital heart conditions. In Vitro Toxicity Testing is generally preferred. Invasive gets a nod only if there is something very complicated to look into. As per trimester, the scheduling of these tests happens.

For the first trimester, it’s early ultrasound, cell-free fetal DNA testing, and cystic fibrosis. Coming to the second trimester, it’s amniocentesis, Quad screen test, ultrasound, and glucose screening. The third trimester involves Group B Strep Screening. The diagnostic tests say chorionic villus sampling.

In-Vitro Toxicology testing

With every type of testing comes in-vitro toxicology testing. The basic advantage is that screening of the drugs happens beforehand, so as to go in sync with the main level of testing – in this case invasive as well as non-invasive prenatal testing. The technologies used herein are inclusive of molecular imaging techniques, cell-cultured technology, genomics, toxic genomics, and others.

Also, for this type of testing happens in animals first. In other words, animal testing is driving the market for in-vitro toxicology testing and the status quo is expected to remain unchanged going forward as well. The mammals are tested herein, so that the inferences can be drawn as to what would be the outcome with humans.

Regional Analysis

North America holds the largest market share with growing incidences of prenatal testing. Also, the number of Down syndrome babies are rising herein. Natera has developed “The Panorama Test” and does work on technology based on SNP (single-nucleotide polymorphism) for analysing DNA. In fact, it holds the distinction of differentiating between fetal and maternal DNA in chromosomes that are of utmost interest. This factor is expected to place the US on the top pedestal undoubtedly.

Europe comes in second on this count. Illumina, Inc., in the year 2017, did announce launching Verse Non Invasive Prenatal Testing (NIPT) Solution in Europe. Plus, EUROCAT states that in Europe close to 104,000 babies have congenital abnormalities, and 8,320 babies out of these suffer from Down syndrome.

This happens every single year. The Asia-Pacific is expected to inch stronger in the upcoming period. This could be attributed to rising demand for diagnosis of the chromosomal disorders at an early stage.

The Competitive Outlook

The key players in the prenatal testing (invasive, non-invasive) market include Quest Diagnostics, GeneDx, Natera, Inc., Prenatal Paternities, Inc., Eurofins NTD Inc., Illumina, Inc., Ariosa Diagnostics, Laboratory Corporation of America Holdings, Ravgen, Sequenom, and Counsyl, Inc. Coming to developments, YOURGENE HEALTH, in March 2020, did acquire AGX-DPNI, so as to make NIPT available in France. Also, Illumina, Inc., in January 2019, did announce launching VeriSeq NIPT Solution v2 that renders availability of precise data regarding status of fetal chromosomes within 10 weeks pf the gestation period.